Ionis Pharmaceuticals IncIONS
Price$44.65

Financial Snapshot

Revenue, profitability, returns, debt, and capital allocation

Revenue $874.1M+24.0% YoYTTM through 30 Jun 2026
Net Income -$565.2MTTM through 30 Jun 2026
Free Cash Flow -$560.8MTTM through 30 Jun 2026

Margins

Current
Gross Margin99.9%
EBITDA Margin-66.5%
Operating Margin-37.6%
Net Margin-64.7%

Returns

-66.7%ROE
-9.5%ROA

Balance Sheet Health

Debt / Equity3.87x
Current Ratio9.66x
Net Debt$1.6B
Cash & Equivalents$350.1M

Quality Metrics

Altman Z-Score0.97
Piotroski F-Score3 / 9
FCF Margin-64.2%
Rule of 40-58.8
Earnings-Beat Rate100.0%

Multi-Year Trend

Revenue
'19'20'21'22'23'24'25
FY2025: $943.7M
Diluted EPS-$3.46TTM
'19'20'21'22'23'24'25
FY2025: $-2.38

Dividend

No dividend

Capital Allocation

Capex Intensity7.4%
All values are periodic snapshots, not live quotes. Source dates are shown for reference.

Filing Detail Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Sign in / Sign up
AI-assisted, source-linked narrative; figures from company filings (SEC EDGAR) and market data. Dates shown per section. Not investment advice. Terms of Use.